8-K 1 a05-1389_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):  January 10, 2005

 

DYAX CORP.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

000-24537

04-3053198

(State or Other Jurisdiction of
Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

300 Technology Square

Cambridge, MA  02139

(Address of Principal Executive Offices)  (Zip Code)

 

(617) 225-2500

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 8.01.                                          Other Events.

 

On January 10, 2005, Dyax Corp. issued a press release announcing interim results from its EDEMA2 (Evaluating DX-88’s Effects on Mitigating Angioedema) trial of DX-88 in hereditary angioedema.  A copy of that press release is attached as Exhibit 99.1.

 

Item 9.01.                                          Financial Statements and Exhibits.

 

(c)                                  Exhibits.

 

99.1                           Press release of Dyax Corp. dated January 10, 2005.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

DYAX CORP.

 

 

 

 

 

 

 

 

Dated:  January 12, 2005

 

By:

/s/ Stephen S. Galliker

 

 

 

 

Stephen S. Galliker

 

 

 

Executive Vice President, Finance

 

 

 

and Administration, and Chief

 

 

 

Financial Officer

 

3


 

EXHIBIT INDEX

 

Exhibit
No.

 

Description

 

 

 

99.1

 

Press release of Dyax Corp. dated January 10, 2005. Filed herewith.

 

4